Form D · Biotechnology

ENDONOVO THERAPEUTICS, INC.

Woodland Hills, CA · CIK 0001528172

Offering snapshot reported Nov 22, 2019 · SEC filing

Reported sold
$225K
Offering amount: $2M
Investors reported
4
Form D · investor count
Minimum accepted
$25K
Reported outside-investor minimum
First sale
Oct 31, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 22, 2019Initial$225,000No comparison4SEC filing
Dec 29, 2017Initial$700,000No comparison13SEC filing
Feb 19, 2016Initial$211,250No comparison6SEC filing
Dec 9, 2014Initial$105,000No comparison3SEC filing
Dec 3, 2014Amendment$50,000$25,000vs Sep 5, 20142SEC filing
Dec 3, 2014Initial$12,500No comparison1SEC filing
Sep 5, 2014Initial$25,000No comparison1SEC filing
Aug 11, 2014Amendment$483,000$473,000vs Nov 15, 201319SEC filing
Nov 15, 2013Initial$10,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06c
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-354045

Source: Form D, filed Nov 22, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Alan Collier Director, Executive
Collier Collier Director, Executive
Michael Mann Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
6320 Canoga Avenue 15 Th Floor
Woodland Hills, CA, 91367